Company Overview and News
The SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is the oldest U.S. ETF. Having launched in 1993, SPY recently celebrated its 25th birthday and it remains the largest ETF. SPY’s $259 billion in assets are more than $100 billion greater than that of its closest rival, the iShares Core S&P 500 ETF (NYSEARCA:IVV), which has $144 billion. A large asset base helps an index fund track its index with precision. SPY also offers tremendous liquidity with nearly $25 billion in daily dollar volume compared to $1.
The markets were more tensed than relaxed in the first quarter of 2018. Increasing inflationary expectations and rising rate fears pushed up bond yields and spurred equity sell-offs in late January and early February. Then, Trump-induced trade fear (thanks to his announcement of import tariffs) and a tech rout in March did the rest of the damage (read: 5 Reason Why FANG ETFs Lost Their Charm in March).
After a sleepy 2017, stock volatility is back in 2018. But, so far this year, long-dated US treasury bonds have failed to provide an offset to sharp stock falls. However, one asset has done well, performing its portfolio hedging task nicely. That's gold. I continue to recommend a meaningful allocation to physical gold (and even more to cash).
February 2018 will be remembered for the brake that the Trump Rally hit after a long and smooth journey. Several market watchers persistently warned of overvaluation and investors have showed amazing patience so far. But the U.S. market crashed to start February.
The global market may have undergone occasional selloffs in 2018 – or the year of dog by Chinese practice – but emerging markets and Asian equities are relatively steady. Emerging-market (EM) ETFs logged their biggest weekly gain last week, since 2016.
Japan has long been enjoying beneficial easy money policies, which have put the economy on a growth path. Japanese markets saw a stellar run in 2017 with equities riding back to heights last seen in 1991 (read: Japan ETFs Will Continue Their Stellar Run in 2018).
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET